Viva Biotech Holdings (1873) AI Stock Analysis

• Market Cap: HK$4.42B
• Dividend Yield: N/A
• Average Volume (3M): 10.31M
• Price to Earnings (P/E): 7.0
• Beta (1Y): 2.30
• Revenue Growth: -8.11%
• EPS Growth: N/A
• Country: HK
• Employees: 2,063
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 2,129,882,300
• 10 Day Avg. Volume: 10,852,121
• 30 Day Avg. Volume: 10,305,290
• PEG Ratio: -0.04
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 9.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): HK$2.17B

• Rating: 55 Neutral
• Price Target: HK$2.50 ▲(42.05% Upside)
• Action: Upgraded Date: 01/27/26
• Date: Action: Upgraded 01/27/26

The score is held back primarily by uneven financial performance—especially operating cash flow dropping to zero and revenue volatility—despite a relatively solid balance sheet and improving profitability in 2024. Technicals are supportive (price above key moving averages and positive MACD) but are tempered by overbought signals (RSI/Stoch). Valuation is also a constraint with a high P/E and no dividend yield data.

Positive Factors

Service-based business model

Viva's core drug discovery and development services, plus partnerships that produce milestone payments and licensing, create diversified revenue channels. This business model is durable: outsourced R&D demand and milestone economics support recurring project work and upsides from successful programs.

Manageable leverage

A relatively low debt-to-equity ratio and strong equity share provide financial flexibility for long-term investments in platforms and partnerships. Manageable leverage reduces interest burden and supports capital deployment for R&D and capacity expansion without immediate refinancing stress.

Improving profitability and solid gross margins

Recovery to positive net income alongside sustained ~35% gross margins indicates the service model can generate healthy unit economics. Persistent gross margins suggest scalable operations and the potential to reinvest earnings into platform development and client acquisition over the medium term.

Negative Factors

Operating cash flow instability

A drop to zero operating cash flow signals weak cash generation from core activities and undermines self-funding ability for R&D and working capital. If this pattern persists, the firm may require external financing, increasing dilution or leverage and constraining strategic flexibility over coming quarters.

Revenue volatility and decline

Declining and volatile revenue reduces predictability of future cash flows and complicates capacity planning and long-term client investment. For a services-driven biotech, inconsistent top-line growth can strain margin sustainability and limit the company's ability to secure longer-term, higher-value partnerships.

Declining cash reserves / liquidity concern

Falling cash reserves weaken the balance sheet's ability to absorb revenue swings or fund up-front project costs. Reduced liquidity heightens the risk of needing unfavorable external capital and can restrict strategic initiatives like platform investment or selective partnerships during downturns.

Viva Biotech Holdings Business Overview & Revenue Model

Company Description

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.

How the Company Makes Money

Viva Biotech generates revenue through multiple key streams primarily centered around its drug discovery and development services. The company charges clients for its specialized services, which include high-throughput screening, lead optimization, and preclinical development. Additionally, Viva Biotech collaborates with pharmaceutical companies through strategic partnerships, often engaging in joint research projects that can lead to milestone payments and royalties upon successful drug development. The company may also earn revenue from licensing agreements for its proprietary technologies or compounds, further diversifying its income sources. These collaborations and services are crucial for driving the company’s financial performance as they cater to the increasing demand for efficient drug development solutions in the competitive biopharmaceutical market.

Viva Biotech Holdings Financial Statement Overview

Summary

Mixed fundamentals: revenue has been volatile and declined from 2022 to 2024, while 2024 net income improved versus prior losses. The balance sheet is relatively solid with manageable leverage (debt-to-equity 0.34) and an equity ratio above 50%, but liquidity quality is a concern due to declining cash reserves and operating cash flow dropping to zero in 2024.

Income Statement

The company's revenue has shown volatility over the years, with a decrease from 2022 to 2024. Gross profit margins have remained strong, averaging around 35%. Net income has improved in 2024 compared to the losses in previous years, signaling a recovery. However, net profit margins have been inconsistent, indicating potential profitability challenges.

Balance Sheet

The company has a stable equity position with a debt-to-equity ratio of 0.34 in 2024, lower than the previous year, indicating manageable leverage. The equity ratio remains above 50%, highlighting a solid financial foundation. However, the decrease in cash reserves over time suggests potential liquidity management issues.

Cash Flow

Operating cash flow has fluctuated significantly, with a concerning drop to zero in 2024. This instability raises questions about the company's ability to generate consistent cash flow from operations. The lack of free cash flow growth further indicates potential challenges in maintaining positive cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.84B	1.99B	2.16B	2.38B	2.10B	696.96M
Gross Profit	687.68M	687.40M	738.43M	815.68M	650.98M	304.87M
EBITDA	427.18M	428.00M	391.01M	436.35M	369.94M	164.35M
Net Income	172.29M	167.29M	-116.11M	-528.48M	287.55M	-386.88M
Balance Sheet
Total Assets	6.88B	7.05B	7.45B	7.92B	8.04B	8.15B
Cash, Cash Equivalents and Short-Term Investments	904.45M	941.58M	1.04B	678.57M	800.95M	2.36B
Total Debt	1.16B	1.28B	1.90B	2.82B	2.65B	2.97B
Total Liabilities	2.98B	3.23B	3.76B	4.32B	4.13B	4.40B
Stockholders Equity	3.89B	3.80B	3.69B	3.60B	3.91B	3.76B
Cash Flow
Free Cash Flow	214.34M	182.32M	195.57M	136.72M	-487.35M	-549.44M
Operating Cash Flow	351.48M	373.99M	383.40M	386.05M	77.83M	43.18M
Investing Cash Flow	-29.84M	185.90M	439.17M	-372.80M	-868.84M	-3.85B
Financing Cash Flow	-455.14M	-657.76M	-429.50M	-143.20M	-653.16M	5.31B

Viva Biotech Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Positive. The current price of 1.76 is below the 20-day moving average (MA) of 2.27, below the 50-day MA of 2.21, and below the 200-day MA of 2.12, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.75 is Neutral, neither overbought nor oversold. The STOCH value of 80.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1873.

Viva Biotech Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	66 Neutral	HK$23.94B	33.55	25.67%	―	2.57%	18.79%
1873	55 Neutral	HK$4.42B	7.02	4.48%	―	-8.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2157	40 Underperform	HK$9.52B	61.57	-21.42%	―	240.05%	-140.09%
1877	38 Underperform	HK$33.75B	-22.62	-14.53%	―	38.56%	48.26%

Viva Biotech Holdings Corporate Events

Viva Biotech Investors Suspend Viva Shanghai Equity Repurchase Rights Until 2028

Viva Biotech Holdings announced that several institutional investors in its subsidiary Viva Shanghai—HLC SPV, Qingdao Hongyi, Daxue Investments, True Light P and Raed Capital Holdings 2 Ltd—have agreed to temporarily suspend their contractual right to require Viva Shanghai and related obligors to repurchase their equity interests if a qualified IPO or M&A is not completed by December 31, 2026. Under the undertaking, these investors will not enforce the repurchase obligation between December 31, 2026 and December 31, 2028, with all other terms of the shareholders’ agreement remaining in force, a move the company says reflects the investors’ confidence in Viva Shanghai’s business prospects and capital-raising plans amid current market conditions and provides the group with additional time and flexibility to execute its strategic options, with further updates to be announced as appropriate.

The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.

Viva Biotech Sells Stake in Arthrosi Therapeutics in Major Merger Deal

Viva Biotech Holdings has announced the disposal of its equity interest in Arthrosi Therapeutics through a merger. The merger agreement, valued at up to US$1.5 billion, will see Viva receiving an initial payment of approximately US$30 million and potential contingent payments based on regulatory and performance milestones. This transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, impacting Viva’s financial assets and potentially enhancing its liquidity and strategic focus.

The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.

Viva Biotech Grants Share Options to Boost Employee Engagement

Viva Biotech Holdings announced the grant of 8,580,000 share options to 44 eligible employees, who are core members of its CDMO operations. These share options are part of the company’s Post-IPO Share Option Scheme and are subject to performance targets, with vesting dates spread across 2028 to 2030. The grant aims to incentivize employees by aligning their performance with the company’s growth targets, which include significant revenue increases over the next few years. This move is expected to enhance employee commitment and drive the company’s growth in the competitive biotech industry.

The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.